SynthesisThrombosis research2014
Guidelines for treatment and prevention of venous thromboembolism among patients with cancer.
Synthesis in Thrombosis research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- COVID-19 (SARS-CoV-2) infection and thrombotic conditions: A systematic review and meta-analysis.European journal of clinical investigation · 2021Pooled it
- Leukemia and Risk of Venous Thromboembolism: A Meta-analysis and Systematic Review of 144 Studies Comprising 162,126 Patients.Scientific reports · 2017Pooled it
- European Myeloma Network guidelines for the management of multiple myeloma-related complications.Haematologica · 2015Guideline
- Universal venous thromboembolism policy is effective but may not adequately protect hospitalized cancer patients with larger BMI.Journal of thrombosis and thrombolysis · 2020Trial
- Clear Cell Ovarian Carcinoma and Its Distinct Coagulopathy Profile: Molecular Drivers and Clinical Implications.Cancer management and research · 2025Review
- The burden and predictors of venous thromboembolic diseases in patients with multiple primary malignancies.Cancer reports (Hoboken, N.J.) · 2023Article
- Tinzaparin-a review of its molecular profile, pharmacology, special properties, and clinical uses.European journal of clinical pharmacology · 2022Review
- Extracellular Vesicle Mediated Vascular Pathology in Glioblastoma.Sub-cellular biochemistry · 2021Article
- Comparative analysis of enoxaparin versus rivaroxaban in the treatment of cancer associated venous thromboembolism: experience from a tertiary care cancer centre.Thrombosis journal · 2020Article
- RNA expression and risk of venous thromboembolism in lung cancer.Research and practice in thrombosis and haemostasis · 2020Article
- The Role of Tinzaparin in Oncology.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis · 2018Review
- Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK).The oncologist · 2018Article
- Acquired Coagulopathy and Hemorrhage Secondary to Subcutaneous Heparin Prophylaxis.Case reports in hematology · 2018Article
- Review
- Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study.Cancer medicine · 2017Article
- Safety and efficacy of primary thromboprophylaxis in cancer patients.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017Review
- The Diagnosis and Treatment of Multiple Myeloma.Deutsches Arzteblatt international · 2016Review
- A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality.The oncologist · 2016Article
- New Direct Oral Anticoagulants (DOAC) and Their Use Today.Dentistry journal · 2016Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The association between cancer and thrombosis has been recognized for more than 150 years. Not only are patients with cancer at a substantially increased risk of developing venous thromboembolism (VTE), the link between several coagulation factors and tumor growth, invasion, and the development of metastases has been established. Reported rates of VTE in patients with cancer have increased in recent years likely reflecting, in part, improved diagnosis with sophisticated imaging techniques as well as the impact of more aggressive cancer diagnosis, staging, and treatment. Various therapeutic interventions, such as surgery, chemotherapy, hormonal therapy, targeted therapeutic strategies as well as the frequent use of indwelling catheters and other invasive procedures also place cancer patients at increased risk of VTE. The increasing risk of VTE, the multitude of risk factors, and the greater risk of VTE recurrence and death among patients with cancer represent considerable challenges in modern clinical oncology. The American Society of Clinical Oncology (ASCO) originally developed guidelines for VTE in patients with cancer in 2007. ASCO recently updated clinical practice guidelines on the treatment and prevention of VTE in patients with cancer following an extensive systematic review of the literature. Revised 2013 guidelines have now been presented and will be discussed in this review. Although several new studies were identified and considered, many important questions remain regarding the relationship between thrombosis and cancer and the optimal care of patients at risk for VTE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.